ALFA Finder| Revenue growth | 38% YoY consolidated growth in FY26. |
|---|---|
| Margins | Consolidated margins dipped due to R&D and bioequivalence study investments. |
| Demand visibility | Strong in chronic therapies (CNS, Urology) and anti-obesity (Semaglutide). |
| Management confidence | High; expanding into 40+ countries with niche portfolios. |
Growth
FY26 consolidated revenue at ₹854cr (up 38% YoY); PAT at ₹46cr (up 20% YoY).
Outlook
Targeting 30% B2C revenue contribution in FY27; guiding 25-30% growth in B2B segment.
Risks
Geopolitical issues delayed B2C launches; forex volatility in Venezuela/Bolivia; high working capital requirements in US distribution.
Earnings Call filed with NSE, NSE: REMUS. Summary written with AI assistance from the document.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹810.90
- Market cap
- ₹955.6 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 25.8×Sector 43.7×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Earnings Call Transcript: Key Takeaways
Remus delivered strong H1 growth led by international operations, though consolidated margins are skewed by a low-margin US distribution transaction.
Remus Pharmaceuticals Investor Presentation: Key Takeaways
H1-FY27 consolidated revenue INR 6,141 Mn (+53.4%) and PAT INR 247 Mn (+14.4%), with EBITDA margin compressing to 4.87%. Standalone PAT rose 56.7%. Growth comes from tender wins and LATAM/SEA expansion.
Remus Pharmaceuticals Results Update
Remus Pharmaceuticals reported H1 FY27 results with standalone revenue of ₹62.08 Cr (up 32.51%) and consolidated revenue of ₹614.12 Cr (up 53.45%). The media release also highlights new tenders, approvals and portfolio expansion across international markets.
Remus Pharmaceuticals Dividend
Remus Pharmaceuticals has fixed 7 November 2026 as the record date for its 1st interim dividend for FY 2026-27, declared at today's board meeting. The filing does not state the per-share dividend amount.
Remus Pharmaceuticals H1 FY27 Results: Net Profit ₹24.7 Cr, Up 14.4% YoY
Remus Pharmaceuticals Ltd reported revenue from operations of ₹614.1 Cr (+53.4% YoY) and net profit of ₹24.7 Cr (+14.4% YoY) for H1 FY27.
- Key figure
- Net profit ₹24.7 Cr · +14.4% YoY
Remus Pharmaceuticals Other Announcement
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.